Home / Stock ratings / Healthcare Stocks / MRK

Stock rating · Pharmaceutical Preparations

Merck & Co., Inc. (MRK) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Merck & Co., Inc. 57 out of 100 (Very Promising). Its highest factor score is earnings track record at 100, and its lowest is catalyst setup at 36.

MELANY ratingRated 2026-11-20

MRK · composite score

57/100
Very Promising
Nov 20
Rating date
Live price in the app →
Quality58
Momentum59
Risk-adjusted55
Source basis SEC filings and live market dataDated snapshot

About Merck & Co., Inc.

Merck makes pharmaceutical products across several therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, its immuno-oncology platform led by Keytruda is a major sales contributor; it also has a substantial vaccine business targeting pediatric diseases plus Gardasil for human papillomavirus, and it sells animal health drugs. Geographically, 47% of sales come from US human health (pharmaceuticals and vaccines).

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why MRK scores 57/100

MRK's 8 factor scores run from 36 to 100, and 4 of them sit above its composite of 57. Here is how MRK breaks down.

Valuation43/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

  • Forward P/E 27.0x, earnings growth accelerating
Business quality58/100

Margins, returns on capital, and balance-sheet strength.

  • Gross margin 72%
Price momentum59/100

Direction and relative strength of the recent share-price trend.

  • 50-day MA above 200-day (golden cross zone)
Earnings track record100/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +22%
Analyst sentiment70/100

What Wall Street price targets and revisions are signalling.

Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile55/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How MRK compares

As of November 20, 2026, Merck & Co., Inc. ranks 17th of 20 in Healthcare Stocks, where the average score is 62.

All stock rating pages.

Key risks for MRK

  • Trailing P/E 135x, priced for sustained growth, any miss could de-rate hard
  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Merck & Co., Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds MRK's momentum and catalyst factors above.

MRK trade plan (Pro)

MELANY has a full position plan for Merck & Co., Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates MRK

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Merck & Co., Inc.'s 57/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about MRK

Is Merck & Co., Inc. (MRK) a buy?

As of 2026-11-20, MELANY rated Merck & Co., Inc. Very Promising with a composite score of 57/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does MRK rank against similar companies?

As of November 20, 2026, Merck & Co., Inc. ranks 17th of 20 in MELANY's Healthcare Stocks list, where the average score is 62. Among the other names in the list, the highest scores belong to REGN (74) and MDT (71).

Should I buy Merck & Co., Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Merck & Co., Inc. (MRK) Very Promising with a composite of 57/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the MRK stock price forecast?

MELANY does not publish price targets or forecasts for MRK. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 57/100 across eight factors for Merck & Co., Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for MRK as of 2026-11-20: its analyst sentiment factor is 70/100, and its price momentum factor is 59/100.

Is MRK stock overvalued or undervalued?

MELANY's valuation factor currently reads 43/100 for Merck & Co., Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MRK's read.

What price should I buy MRK at?

Rather than chasing the current price, MELANY computes a smart entry zone for MRK: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying MRK stock?

The top risks MELANY currently flags for Merck & Co., Inc.: Trailing P/E 135x, priced for sustained growth, any miss could de-rate hard; Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Merck & Co., Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 58/100 for Merck & Co., Inc., and earnings track record, at 100/100. The 57/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will MRK stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 59/100 for MRK right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this MRK rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores MRK as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, MRK included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.